The Waltham, Massachusetts-based company, which was incorporated in 2019, plans to use the IPO proceeds to advance the clinical development of obexelimab and prepare for its potential launch in the United States and Europe, pending approval.
News
Zenas BioPharma raises $225 mln in US IPO
October 21, 2024The Waltham, Massachusetts-based company, which was incorporated in 2019, plans to use the IPO proceeds to advance the clinical development of obexelimab and prepare for its potential launch in the United States and Europe, pending approval.